Ariceum Therapeutics

About Ariceum Therapeutics

• Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on developing novel targeted radiopharmaceuticals for the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.
• Their lead product, Satoreotide, is being developed as a theranostic pair for combined diagnosis and targeted radionuclide treatment.
• The company has operations in Germany, Switzerland, Australia, the UK and the US.

Ariceum Therapeutics is listed on Rocketlist with 2 active roles. The company is categorized as Radiopharmaceuticals in BioTech. Ariceum Therapeutics is at Series A stage, with a B2B business model, headquartered in Berlin, Germany. Ariceum Therapeutics was founded in 2021 and has 33 employees. Ariceum Therapeutics has raised $52M. Active roles are refreshed daily from public hiring sources.

Open roles at Ariceum Therapeutics (2)